Diagnostic yield, safety, and impact of transbronchial lung biopsy in mechanically ventilated, critically ill patients: a retrospective study.


Journal

BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563

Informations de publication

Date de publication:
07 Jan 2021
Historique:
received: 04 08 2020
accepted: 23 11 2020
entrez: 8 1 2021
pubmed: 9 1 2021
medline: 7 9 2021
Statut: epublish

Résumé

Pulmonary infiltrates of variable etiology are one of the main reasons for hypoxemic respiratory failure leading to invasive mechanical ventilation. If pulmonary infiltrates remain unexplained or progress despite treatment, the histopathological result of a lung biopsy could have significant impact on change in therapy. Surgical lung biopsy is the commonly used technique, but due to its considerable morbidity and mortality, less invasive bronchoscopic transbronchial lung biopsy (TBLB) may be a valuable alternative. Retrospective, monocentric, observational study in mechanically ventilated, critically ill patients, subjected to TBLB due to unexplained pulmonary infiltrates in the period January 2014 to July 2019. Patients' medical records were reviewed to obtain data on baseline clinical characteristics, modality and adverse events (AE) of the TBLB, and impact of the histopathological results on treatment decisions. A multivariable binary logistic regression analysis was performed to identify predictors of AE and hospital mortality, and survival curves were generated using the Kaplan-Meier method. Forty-two patients with in total 42 TBLB procedures after a median of 12 days of mechanical ventilation were analyzed, of which 16.7% were immunosuppressed, but there was no patient with prior lung transplantation. Diagnostic yield of TBLB was 88.1%, with AE occurring in 11.9% (most common pneumothorax and minor bleeding). 92.9% of the procedures were performed as a forceps biopsy, with organizing pneumonia (OP) as the most common histological diagnosis (54.8%). Variables independently associated with hospital mortality were age (odds ratio 1.070, 95%CI 1.006-1.138; p = 0.031) and the presence of OP (0.182, [0.036-0.926]; p = 0.040), the latter being confirmed in the survival analysis (log-rank p = 0.040). In contrast, a change in therapy based on histopathology alone occurred in 40.5%, and there was no evidence of improved survival in those patients. Transbronchial lung biopsy remains a valuable alternative to surgical lung biopsy in mechanically ventilated critically ill patients. However, the high diagnostic yield must be weighed against potential adverse events and limited consequence of the histopathological result regarding treatment decisions in such patients.

Sections du résumé

BACKGROUND BACKGROUND
Pulmonary infiltrates of variable etiology are one of the main reasons for hypoxemic respiratory failure leading to invasive mechanical ventilation. If pulmonary infiltrates remain unexplained or progress despite treatment, the histopathological result of a lung biopsy could have significant impact on change in therapy. Surgical lung biopsy is the commonly used technique, but due to its considerable morbidity and mortality, less invasive bronchoscopic transbronchial lung biopsy (TBLB) may be a valuable alternative.
METHODS METHODS
Retrospective, monocentric, observational study in mechanically ventilated, critically ill patients, subjected to TBLB due to unexplained pulmonary infiltrates in the period January 2014 to July 2019. Patients' medical records were reviewed to obtain data on baseline clinical characteristics, modality and adverse events (AE) of the TBLB, and impact of the histopathological results on treatment decisions. A multivariable binary logistic regression analysis was performed to identify predictors of AE and hospital mortality, and survival curves were generated using the Kaplan-Meier method.
RESULTS RESULTS
Forty-two patients with in total 42 TBLB procedures after a median of 12 days of mechanical ventilation were analyzed, of which 16.7% were immunosuppressed, but there was no patient with prior lung transplantation. Diagnostic yield of TBLB was 88.1%, with AE occurring in 11.9% (most common pneumothorax and minor bleeding). 92.9% of the procedures were performed as a forceps biopsy, with organizing pneumonia (OP) as the most common histological diagnosis (54.8%). Variables independently associated with hospital mortality were age (odds ratio 1.070, 95%CI 1.006-1.138; p = 0.031) and the presence of OP (0.182, [0.036-0.926]; p = 0.040), the latter being confirmed in the survival analysis (log-rank p = 0.040). In contrast, a change in therapy based on histopathology alone occurred in 40.5%, and there was no evidence of improved survival in those patients.
CONCLUSIONS CONCLUSIONS
Transbronchial lung biopsy remains a valuable alternative to surgical lung biopsy in mechanically ventilated critically ill patients. However, the high diagnostic yield must be weighed against potential adverse events and limited consequence of the histopathological result regarding treatment decisions in such patients.

Identifiants

pubmed: 33413299
doi: 10.1186/s12890-020-01357-7
pii: 10.1186/s12890-020-01357-7
pmc: PMC7788549
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

15

Références

J Bronchology Interv Pulmonol. 2014 Jul;21(3):199-207
pubmed: 24992127
Respir Med. 2012 Nov;106(11):1559-65
pubmed: 22938740
Eur Respir J. 2003 Mar;21(3):489-94
pubmed: 12662007
J Heart Lung Transplant. 2003 Mar;22(3):267-75
pubmed: 12633693
Respir Res. 2019 Jul 5;20(1):140
pubmed: 31277659
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
Chest. 2007 Apr;131(4):954-63
pubmed: 17426195
J Bronchology Interv Pulmonol. 2020 Jan;27(1):36-41
pubmed: 31725496
BMC Pulm Med. 2019 Mar 1;19(1):56
pubmed: 30823915
N Engl J Med. 1985 Jan 17;312(3):152-8
pubmed: 3965933
Ann Am Thorac Soc. 2015 Aug;12(8):1226-30
pubmed: 26065712
Eur Respir J. 1996 Dec;9(12):2513-6
pubmed: 8980962
JAMA. 1998 Jul 8;280(2):159-65
pubmed: 9669790
Lancet Respir Med. 2020 Feb;8(2):171-181
pubmed: 31578168
Chest. 1986 Feb;89(2):168-70
pubmed: 3943376
Eur Respir J. 2006 Aug;28(2):422-46
pubmed: 16880372
Am J Respir Crit Care Med. 2013 Jul 15;188(2):220-30
pubmed: 23631814
Crit Care Med. 2018 Jun;46(6):907-914
pubmed: 29521713
Crit Care Med. 1987 Dec;15(12):1136-9
pubmed: 3677765
Crit Care Med. 1997 Mar;25(3):440-6
pubmed: 9118660
Am J Respir Crit Care Med. 2016 May 15;193(10):1161-7
pubmed: 26646481
Chest. 2002 Oct;122(4):1461-4
pubmed: 12377879
Eur Respir J. 2016 Nov;48(5):1453-1461
pubmed: 27660509
Can Respir J. 2017;2017:1565030
pubmed: 29430203

Auteurs

Alessandro Ghiani (A)

Department of Pulmonary and Respiratory Medicine, Schillerhoehe Lung Clinic (Robert-Bosch-Hospital GmbH, Stuttgart), Solitudestr. 18, 70839, Gerlingen, Germany. alessandro.ghiani@klinik-schillerhoehe.de.

Claus Neurohr (C)

Department of Pulmonary and Respiratory Medicine, Schillerhoehe Lung Clinic (Robert-Bosch-Hospital GmbH, Stuttgart), Solitudestr. 18, 70839, Gerlingen, Germany.
German Center for Lung Research (DZL), Germany, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH